Cover Image
市場調查報告書

全球皮膚科市場:至2028年的預測

The Global Dermatology Market to 2028

出版商 GMR Data Ltd 商品編碼 384190
出版日期 內容資訊 英文 180 Pages
訂單完成後即時交付
價格
Back to Top
全球皮膚科市場:至2028年的預測 The Global Dermatology Market to 2028
出版日期: 2018年06月04日 內容資訊: 英文 180 Pages
簡介

全球皮膚疾病治療藥 (處方藥) 市場,2017年是384億美金。該市場,預計2018年達到441億美元。

本報告提供全球皮膚疾病治療藥的市場相關調查分析,皮膚疾病的各種區分,目前治療方法,新藥的研究開發趨勢,市場規模的變化與預測,主要企業的簡介,專家的見解等彙整資料,為您概述為以下內容。

第1章 摘要整理

第2章 全球皮膚科市場上目前趨勢、發展

  • 目前趨勢,課題及發展
  • 皮膚科的生技藥品
  • M&A

第3章 全球皮膚科治療藥市場、預測

  • 全球市場概要
  • 全球皮膚科治療藥市場:各類型

第4章 全球尋常痤瘡 (粉刺)的處方藥市場、預測

  • 種類與症狀
  • 發病率和盛行率
  • 主要趨勢
  • 目前處方治療
  • 市場規模與預測
  • 已上市治療藥的市場與預測
  • 第三階段開發平台的預測
  • 第二階段開發平台的預測
  • 競爭分析

第5章 全球乾癬的處方藥市場、預測

  • 種類與症狀
  • 發病率和盛行率
  • 主要趨勢
  • 目前處方治療
  • 市場規模與預測
  • 已上市治療藥的市場與預測
  • 第三階段開發平台的預測
  • 第二階段開發平台的預測
  • 競爭分析

第6章 全球脫髮症的處方藥市場、預測

  • 種類與症狀
  • 發病率和盛行率
  • 主要趨勢
  • 目前處方治療
  • 市場規模與預測
  • 已上市治療藥的市場與預測
  • 第三階段開發平台的預測
  • 第二階段開發平台的預測
  • 競爭分析

第7章 全球皮膚癌的處方藥市場、預測

  • 種類與症狀
  • 發病率和盛行率
  • 主要趨勢
  • 目前處方治療
  • 市場規模與預測
  • 已上市治療藥的市場與預測
  • 第三階段開發平台的預測
  • 第二階段開發平台的預測
  • 競爭分析

第8章 全球皮膚感染疾病的處方藥市場、預測

  • 種類與症狀
  • 發病率和盛行率
  • 主要趨勢
  • 目前處方治療
  • 市場規模與預測
  • 已上市治療藥的市場與預測
  • 第三階段開發平台的預測
  • 第二階段開發平台的預測
  • 競爭分析

第9章 全球異位性皮膚炎的處方藥市場、預測

  • 種類與症狀
  • 發病率和盛行率
  • 主要趨勢
  • 目前處方治療
  • 市場規模與預測
  • 已上市治療藥的市場與預測
  • 第三階段開發平台的預測
  • 第二階段開發平台的預測
  • 競爭分析

第10章 全球酒糟的處方藥市場、預測

  • 種類與症狀
  • 發病率和盛行率
  • 主要趨勢
  • 目前處方治療
  • 市場規模與預測
  • 已上市治療藥的市場與預測
  • 競爭分析

第11章 全球皮膚科部門的主要國家市場

  • 美國的皮膚科治療藥市場、預測
  • 英國的皮膚科治療藥市場、預測
  • 法國的皮膚科治療藥市場、預測
  • 德國的皮膚科治療藥市場、預測
  • 西班牙的皮膚科治療藥市場、預測
  • 義大利的皮膚科治療藥市場、預測
  • 日本的皮膚科治療藥市場、預測
  • 其他地區的皮膚科治療藥市場、預測

第12章 專家的見解

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DERMA28

The global dermatological (prescription) drugs market was valued at $38.4bn in 2017, GMR Data forecast that this will rise to $44.1bn across 2018.

The third in a series of biennial Dermatology reports sees GMR Data again interview industry experts to produce a market leading report that dissects and investigates the key questions in the Global Dermatology Market across the next decade.

GMR Data forecasts that the global dermatology (prescription) drugs market will report a CAGR of 6.4% across 2018 and 2028.

Of the seven dermatological drugs types / segments highlighted in the report, Atopic Dermatitis and Skin Cancer are estimated to display the highest growth rates (10-year CAGR) of 12.8% and 9.2% respectively.

GMR Data attributes this growth to a change in treatment modalities of the mentioned dermatological diseases. The new treatment modality widely uses a targeted approach of 'biological' drugs that are specific, highly efficacious and result in high QALY; for instance - MoAbs or monoclonal antibodies witnessed higher adoption rates in Atopic Dermatitis.

5 Reasons why you must read this report today:

  • 1. Dermatology drug manufacturers are enjoying higher revenues than ever before in this niche market and with increasing prevalence of skin diseases, this will continue across the next decade.
  • 2. A number of leading drugs are set to come off of patent across the forecast period.
  • 3. Pipeline products addressing areas of unmet clinical need, especially in the acne, skin infections and skin cancer markets with the potential to become blockbusters, will launch during the forecast period.
  • 4. Understanding the areas of the market in which growth will occur allows for a more tailored approach to expansion, increasing the chances of success.
  • 5. GMR Data's report gives an in depth and independent view of the leading companies in the dermatology drugs market, ensuring you have all the information needed when moving forward.

Included in the report is analysis of the leading companies and geographies in the dermatology drugs market, as well as of the opportunities and threats facing manufacturers. The report has forecasts for all key submarkets in the market as well as for the leading drugs.

The primary companies in the market are studied with pipeline products and merger & acquisitions in relation to the dermatology sector.

This independent, 180 page report guarantees you will remain better informed than your competition. With over 150 tables and figures examining the dermatology drugs market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leaders market revenue forecasts as well as analysis to 2028, which keeps your knowledge that one step ahead, helping you to succeed. This report is essential reading for you or anyone in the pharmaceutical or health care sectors. Purchasing this report today will help you to recognise those important market opportunities and understand the possibilities there.

Table of Contents

1 - Executive Summary

  • 1.1 Executive Summary
  • 1.2 Report Description
  • 1.3 Market Segmentation
  • 1.4 Research Methodology

2 - Current Trends & Developments in the Global Dermatology Market

  • 2.1 Current Trends, Challenges & Developments
    • 2.1.1. Historic Limited Economic Potential - Changed with Introduction of Biologics
    • 2.1.2. Stringent Regulatory Norms for Clearance
    • 2.1.3. Switch from Prescription to OTC
    • 2.1.4. Difficulty with Combination Drugs
  • 2.2 Biologics in Dermatology
  • 2.3 Mergers and Acquisitions

3 - Global Dermatological Drugs Market & Forecast, 2018 - 2028

  • 3.1 Global Market Overview
  • 3.2 Global Dermatological Drugs Market by Type

4 - Global Acne Vulgaris Prescription Drugs Market & Forecast, 2018 - 2028

  • 4.1 Types and Symptoms of Acne Vulgaris
  • 4.2 Incidence and Prevalence of Acne Vulgaris
  • 4.3 Key Trends in the Global Acne Vulgaris Market
  • 4.4 Current Prescription (rx) Treatments for Acne Vulgaris
  • 4.5 Global Acne Vulgaris Market Size &Forecast, 2018 - 2028
  • 4.6 Current Marketed Drugs & Forecast
    • 4.6.1. Solodyn Market and Forecast
    • 4.6.2. Doryx Market and Forecast
    • 4.6.3. Epiduo Market and Forecast
  • 4.7 Acne Vulgaris - Phase III Drugs Pipeline Forecast
    • 4.7.1. Onexton (Valeant)
    • 4.7.2. Epiduo Forte (Galderma)
    • 4.7.3. Sarecycline (Actavis)
  • 4.8 Acne Vulgaris - Phase II Drugs Pipeline Forecast
    • 4.8.1. DRM01 (Dermira)
    • 4.8.2. FMX101 (Foamix)
    • 4.8.3. SB204 (Novan Therapeutics)
    • 4.8.4. SEB002 (Sebacia)
    • 4.8.5. MTC896 (Mimetica)
  • 4.9 Competitive Analysis in the Acne Vulgaris Market
    • 4.9.1. Valeant Pharmaceuticals
    • 4.9.2. Dermira
    • 4.9.3. Paratek Pharmaceuticals
    • 4.9.4. Mayne Pharma

5 - Global Psoriasis Prescription Drugs Market & Forecast, 2018 - 2028

  • 5.1 Types & Symptoms of Psoriasis
  • 5.2 Incidence & Prevalence of Psoriasis
  • 5.3 Key Trends in the Global Psoriasis Market
  • 5.4 Current Prescription (Rx) Treatments for Psoriasis
  • 5.5 Global Psoriasis Market Size & Forecast, 2018 - 2028
  • 5.6 Current Marketed Drugs & Forecast
    • 5.6.1. Stelara (Psoriasis) Market and Forecast
    • 5.6.2. Enbrel (Psoriasis) Market and Forecast
    • 5.6.3. Humira (Psoriasis) Market and Forecast
    • 5.6.4. Otezla (Psoriasis) Market and Forecast
    • 5.6.5. Cosentyx (Psoriasis) Market and Forecast
    • 5.6.6. Taltz (Psoriasis) Market and Forecast
    • 5.6.7. Piclidenoson (Psoriasis) Market and Forecast
  • 5.7 Psoriasis - Phase III Drugs (Injectable Biologics) Pipeline Forecast
    • 5.7.1. BI 655066 (Boehringer Ingelheim)
    • 5.7.2. Guselkumab (Janssen)
    • 5.7.3. Tildrakizumab (Sun Pharma)
  • 5.8 Psoriasis - Phase III Drugs (Injectable Biologics) Pipeline Forecast
    • 5.8.1. Cimzia (UBC)
    • 5.8.2. Brodalumab (Astra-Zeneca/Valeant)
  • 5.9 Psoriasis - Phase II Drugs (Injectable Biologics) Pipeline Forecast
    • 5.9.1. Tregalizumab (Biotest AG)
    • 5.9.2. Namilumab (Takeda Pharmaceuticals)
    • 5.9.3. IMO-8400 (Idera Pharmaceuticals)
  • 5.10 Psoriasis - Phase II (10) Drugs (Orally Administered) Pipeline Forecast
  • 5.11 Competitive Analysis In Psoriasis Market
    • 5.11.1. Celgene Corporation
    • 5.11.2. Novartis
    • 5.11.3. Can-Fite BioPharma

6 - Global Alopecia Prescription Drugs Market & Forecast, 2018 - 2028

  • 6.1 Types and Symptoms of Alopecia
  • 6.2 Incidence and Prevalence Of Alopecia
  • 6.3 Key Trends in The Global Alopecia Market
  • 6.4 Current Prescription (Rx) Treatments for Alopecia
  • 6.5 Global Alopecia Market Size And Forecast, 2018 - 2028
  • 6.6 Current Marketed Drugs and Forecast
    • 6.6.1. Propecia Market and Forecast
  • 6.7 Alopecia - Phase III Drugs Pipeline Forecast
    • 6.7.1. Bimatoprost (Allergan)
    • 6.7.2. SM04554 (Samumed)
  • 6.8 alopecia - phase II (2) Drugs Pipeline Forecast
  • 6.9 Competitive Analysis In Alopecia Market
    • 6.9.1. Merck
    • 6.9.2. Samumed
    • 6.9.3. Concert Pharmaceuticals

7 - Global Skin Cancer Prescription Drugs Market & Forecast, 2018 - 2028

  • 7.1 Types and Symptoms of Skin Cancer
  • 7.2 Incidence and Prevalence of Skin Cancer
  • 7.3 Key Trends in the Global Skin Cancer Market
  • 7.4 Current Prescription (Rx) Treatments for Skin Cancer
  • 7.5 Global Skin Cancer Market Size and Forecast, 2018 - 2028
  • 7.6 Current Marketed Drugs and Forecast
    • 7.6.1. Yervoy Market and Forecast
    • 7.6.2. Zelboraf + Cotellic Market and Forecast
    • 7.6.3. Tafinlar + Mekinist Market and Forecast
    • 7.6.4. Keytruda Market and Forecast
    • 7.6.5. Opdivo, Opdivo + Yervoy Market and Forecast
    • 7.6.6. Imlygic Market and Forecast
    • 7.6.7. Erivedge Market and Forecast
    • 7.6.8. Odomzo Market and Forecast
  • 7.7 Skin Cancer - Phase III (12) Drugs Pipeline Forecast
  • 7.8 Skin Cancer - Phase II (53) Drugs Pipeline Forecast
  • 7.9 Competitive Analysis In Skin Cancer Market
    • 7.9.1. Roche Holding (Roche)
    • 7.9.2. Sun Pharmaceutical Industries

8 - Global Skin Infections Prescription Drugs Market & Forecast, 2018 - 2028

  • 8.1 Types and Symptoms of Skin Infections
  • 8.2 Incidence and Prevalence of Skin Infections
  • 8.3 Key Trends in the Global Skin Infections Market
  • 8.4 Current Prescription (Rx) Treatments for Skin Infections
  • 8.5 Global Skin Infections Market Size and Forecast, 2018 - 2028
  • 8.6 Current Marketed Drugs and Forecast - cSSSIS
    • 8.6.1. Cubicin Market and Forecast
    • 8.6.2. Zyvox Market and Forecast
    • 8.6.3. Sivextro Market and Forecast
    • 8.6.4. Orbactiv Market and Forecast
    • 8.6.5. Dalvance Market and Forecast
    • 8.6.6. Tygacil Market and Forecast
    • 8.6.7. Teflaro Market and Forecast
  • 8.7 Current Marketed Drugs and Forecast - Onychomycosis
    • 8.7.1. Kerydin Market and Forecast
    • 8.7.2. Jublia Market and Forecast
  • 8.8 Skin Infections - Phase III (11) Drugs (cSSSIS) Pipeline Forecast
  • 8.9 Skin Infections - Phase III (3) Drugs (Onychomycosis) Pipeline Forecast
  • 8.10 Skin Infections - Phase Ii (3) Drugs (Onychomycosis) Pipeline Forecast
  • 8.11 Competitive Analysis in the Skin Infections Market
    • 8.11.1. Novan Therapeutics

9 - Global Atopic Dermatitis Prescription Drugs Market & Forecast, 2018 - 2028

  • 9.1 Types and Symptoms of Dermatitis
  • 9.2 Incidence and Prevalence of Atopic Dermatitis
  • 9.3 Key Trends in the Dermatitis Market
  • 9.4 Current Prescription (Rx) Treatments for Dermatitis
  • 9.5 Global Atopic Dermatitis Market Size and Forecast, 2018 - 2028
  • 9.6 Current Marketed Drugs and Forecast
    • 9.6.1. Dupixent Market and Forecast
    • 9.6.2. Eucrisa Market and Forecast
  • 9.7 Atopic Dermatitis - Phase III Drugs Pipeline Forecast
    • 9.7.1. ZPL-389 (Ziarco Pharma)
    • 9.7.2. Nanocyclo (Immune Pharmaceuticals)
  • 9.8 Atopic Dermatitis - Phase II Drugs (Orally/Topically Administered) Pipeline Forecast
    • 9.8.1. Tofactinib/Xeljanz (Pfizer)
    • 9.8.2. ZPL-521 (Ziarco Pharma)
    • 9.8.3. OPA-15406 (Otsuka/Medimetriks)
    • 9.8.4. Upadacitinib (AbbVie)
    • 9.8.5. Baricitinib (Eli Lilly/Incyte)
  • 9.9 Atopic Dermatitis - Phase II Drugs (Injectable Moabs) Pipeline Forecast
    • 9.9.1. Bertilimumab (Immune Pharmaceuticals)
    • 9.9.2. Tralokinumab (Leo Pharma/Astra-Zeneca)
    • 9.9.3. Nemolizumab (Chugai Pharmaceuticals)
    • 9.9.4. Lebrikizumab (Roche/Genentech)
  • 9.10 Competitive Analysis in the Atopic Dermatitis Market
    • 9.10.1. Sanofi
    • 9.10.2. Pfizer
    • 9.10.3. Immune Pharmaceuticals

10 - Global Rosacea Prescription Drugs Market & Forecast, 2018 - 2028

  • 10.1 Types and Symptoms of Rosacea
  • 10.2 Incidence and Prevalence of Rosacea
  • 10.3 Key Trends in the Global Rosacea Market
  • 10.4 Current Prescription (Rx) Treatments for Rosacea
  • 10.5 Global Rosacea Market Size and Forecast, 2018 - 2028
  • 10.6 Current Marketed Drugs and Forecast
    • 10.6.1. Finacea Gel + Finacea Foam (Bayer/Foamix)
    • 10.6.2. Mirvaso (Galderma)
    • 10.6.3. Soolantra (Galderma)
    • 10.6.4. Oracea (Galderma)
    • 10.6.5. Rhofade (Allergan)
  • 10.7 Competitive Analysis in Rosacea Market
    • 10.7.1. Bayer
    • 10.7.2. Galderma (Nestle Skin Health)
    • 10.7.3. Allergan

11 - Key National Markets in the Global Dermatology Sector, 2018 - 2028

  • 11.1 U.S Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.2 U.K. Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.3 France Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.4 Germany Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.5 Spain Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.6 Italy Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.7 Japan Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.8 Row Dermatological Drugs Market and Forecast, 2018 - 2028
    • 11.8.1. Brazil Dermatological Drugs Market and Forecast, 2018 - 2028
    • 11.8.2. Russia Dermatological Drugs Market and Forecast, 2018 - 2028
    • 11.8.3. India Dermatological Drugs Market and Forecast, 2018 - 2028
    • 11.8.4. China Dermatological Drugs Market and Forecast, 2018 - 2028

12 - Expert Opinion

  • 12.1 Galderma
  • 12.2 Ranbaxy

Appendix: Skin Cancer - Phase III & Phase II Drugs Pipeline

Back to Top